Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.

Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, Vokes EE, Ratain MJ.

J Clin Oncol. 2004 Apr 15;22(8):1382-8. Epub 2004 Mar 8.

2.

Clinical and pharmacogenetic factors associated with irinotecan toxicity.

Kweekel D, Guchelaar HJ, Gelderblom H.

Cancer Treat Rev. 2008 Nov;34(7):656-69. doi: 10.1016/j.ctrv.2008.05.002. Epub 2008 Jun 16. Review.

PMID:
18558463
3.

Pharmacogenetics of irinotecan disposition and toxicity: a review.

Fujita K, Sparreboom A.

Curr Clin Pharmacol. 2010 Aug;5(3):209-17. Review.

PMID:
20406168
4.

Clinical pharmacogenetics of irinotecan (CPT-11).

Ando Y, Hasegawa Y.

Drug Metab Rev. 2005;37(3):565-74. Review.

PMID:
16257834
5.

UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.

Biason P, Masier S, Toffoli G.

J Chemother. 2008 Apr;20(2):158-65. Review.

PMID:
18467239
6.

Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question.

Deeken JF, Slack R, Marshall JL.

Cancer. 2008 Oct 1;113(7):1502-10. doi: 10.1002/cncr.23777. Review.

7.

Pharmacogenetics and irinotecan therapy.

Hahn KK, Wolff JJ, Kolesar JM.

Am J Health Syst Pharm. 2006 Nov 15;63(22):2211-7. Review.

PMID:
17090741
8.

UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians.

Cheng L, Li M, Hu J, Ren W, Xie L, Sun ZP, Liu BR, Xu GX, Dong XL, Qian XP.

Cancer Chemother Pharmacol. 2014 Mar;73(3):551-60. doi: 10.1007/s00280-014-2382-3. Epub 2014 Jan 22. Review.

PMID:
24448639
9.

[UGT1A1 Genotyping for Proper Use of Irinotecan].

Matsuoka A, Ando Y.

Rinsho Byori. 2015 Jul;63(7):876-82. Review. Japanese.

PMID:
26591441
10.

Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.

Palomaki GE, Bradley LA, Douglas MP, Kolor K, Dotson WD.

Genet Med. 2009 Jan;11(1):21-34. doi: 10.1097/GIM.0b013e31818efd77. Review.

11.

Insights, challenges, and future directions in irinogenetics.

Kim TW, Innocenti F.

Ther Drug Monit. 2007 Jun;29(3):265-70. Review.

PMID:
17529881
12.

Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.

Innocenti F, Ratain MJ.

Oncology (Williston Park). 2003 May;17(5 Suppl 5):52-5. Review.

PMID:
12800608
13.

Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis.

Hu ZY, Yu Q, Zhao YS.

Eur J Cancer. 2010 Jul;46(10):1856-65. doi: 10.1016/j.ejca.2010.02.049. Epub 2010 Mar 23. Review.

PMID:
20335017
14.

UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?

Schulz C, Boeck S, Heinemann V, Stemmler HJ.

Anticancer Drugs. 2009 Nov;20(10):867-79. doi: 10.1097/CAD.0b013e328330c7d2. Review.

PMID:
19770637
15.

UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy.

Ando Y, Fujita K, Sasaki Y, Hasegawa Y.

Curr Opin Mol Ther. 2007 Jun;9(3):258-62. Review.

PMID:
17608024
16.

Irinotecan pharmacogenomics.

Marsh S, Hoskins JM.

Pharmacogenomics. 2010 Jul;11(7):1003-10. doi: 10.2217/pgs.10.95. Review.

17.

Pharmacogenetics of irinotecan toxicity.

Marsh S, McLeod HL.

Pharmacogenomics. 2004 Oct;5(7):835-43. Review.

PMID:
15469406
18.

[Relationship between UGT1A and irinotecan-related toxicity].

Xu JM.

Zhonghua Zhong Liu Za Zhi. 2013 Apr;35(4):241-3. doi: 10.3760/cma.j.issn.0253-3766.2013.04.001. Review. Chinese. No abstract available.

PMID:
23985249
19.

Pharmacogenetics of irinotecan.

Toffoli G, Cecchin E, Corona G, Boiocchi M.

Curr Med Chem Anticancer Agents. 2003 May;3(3):225-37. Review.

PMID:
12769780
20.

Screening for adverse reactions to irinotecan treatment using the Invader UGT1A1 Molecular Assay.

Hasegawa Y, Ando Y, Shimokata K.

Expert Rev Mol Diagn. 2006 Jul;6(4):527-33. Review.

PMID:
16824027
Items per page

Supplemental Content

Write to the Help Desk